Abstract:ABSTRACT In the context of pharmacogenomics, whole genome sequencing provides a powerful approach for identifying correlations between response variability to specific drugs and genomic polymorphisms in a population, in an unbiased manner. In this study, we employed whole genome sequencing of DNA samples from patients showing extreme response (n=72) and non-response (n=27) to the antiepileptic drug levetiracetam, in order to identify genomic variants that underlie response to the drug. Although no common SNP (MAF>5%) crossed the conventional genome-wide significance threshold of 5×10 −8 , we found common polymorphisms in genes SPNS3, HDC, MDGA2, NSG1 and RASGEF1C , which collectively predict clinical response to levetiracetam in our cohort with ∼91% predictive accuracy (∼94% positive predictive value, ∼85% negative predictive value). Among these genes, HDC, NSG1, MDGA2 and RASGEF1C are potentially implicated in synaptic neurotransmission, while SPNS3 is an atypical solute carrier transporter homologous to SV2A , the known molecular target of levetiracetam. Furthermore, we performed gene- and pathway-based statistical analysis on sets of rare and low-frequency variants (MAF<5%) and we identified associations between genes or pathways and response to levetiracetam. Our findings include a) the genes PRKCB and DLG2 , which are involved in glutamatergic neurotransmission, a known target of anticonvulsants, including levetiracetam; b) the genes FILIP1 and SEMA6D , which are involved in axon guidance and modelling of neural connections; and c) pathways with a role in synaptic neurotransmission, such as WNT5A-dependent internalization of FZD4 and disinhibition of SNARE formation . Targeted analysis of genes involved in neurotransmitter release and transport further supports the possibility of association between drug response and genes NSG1 and DLG2 . In summary, our approach to utilise whole genome sequencing on subjects with extreme response phenotypes is a feasible route to generate plausible hypotheses for investigating the genetic factors underlying drug response variability in cases of pharmaco-resistant epilepsy. AUTHOR SUMMARY Levetiracetam (LEV) is a prominent antiepileptic drug prescribed for the treatment of both focal and generalised epilepsy. The molecular mechanism mediating its action is not well understood, but it involves the modulation of synaptic neurotransmition through binding to the synaptic vesicle glycoprotein SV2A. Identifying genomic polymorphisms that predict response to the drug is important, because it can help clinicians prescribe the most appropriate treatment in a patient-specific manner. In this study, we employed whole genome sequencing (WGS) of DNA samples from extreme responders or non-responders to LEV and we identified a small group of common variants, which successfully predict response to the drug in our cohort. These variants are mostly located in genes implicated in synaptic function. Furthermore, we identified significant associations between clinical response to LEV and low-frequency variants in genes and pathways involved in excitatory neurotransmission or in the moulding of neural networks in the brain. Our approach to utilise WGS on subjects with extreme response phenotypes is a feasible route to generate plausible hypotheses on the genomic basis of pharmaco-resistant epilepsy. We expect that the rapidly decreasing cost of WGS will allow conducting similar studies on a larger scale in the near future.

Levetiracetam-Induced Cutaneous Adverse Drug Reactions Were Not Associated with Hla Genes in A Small Sample of Chinese Patients with Epilepsy

Association Study of Lamotrigine-Induced Cutaneous Adverse Reactions and HLA-B*1502 in a Han Chinese Population

Hla-A*24:02 As A Common Risk Factor for Antiepileptic Drug-Induced Cutaneous Adverse Reactions

HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?

An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

The association between AED-induced cutaneous adverse drug reactions and the HLA-A, -B, and -DRB1 alleles among Caucasian patients: a pilot multicenter study

Association Between HLA-A*3201 Allele and Oxcarbazepine-Induced Cutaneous Adverse Reactions in Eastern Han Chinese Population

Progress on Relation Between Human Leukocyte Antigen Gene and Oxcarbazepine Induced Cutaneous Adverse Drug Reactions

Pilot Association Study of Oxcarbazepine-Induced Mild Cutaneous Adverse Reactions with HLA-B*1502 Allele in Chinese Han Population

Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy

Genetic Predictors of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Aromatic Antiepileptic Drugs among the Chinese Han Population

HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients.

Association of a Polymorphism in MDR1C3435T with Intractable Epilepsy of Children

Whole genome sequencing identifies putative associations between genomic polymorphisms and clinical response to the antiepileptic drug levetiracetam

The HLA‐DRB1 Shared Epitope is Not Associated with Antibodies Against Cyclic Citrullinated Peptide in Chinese Patients with Rheumatoid Arthritis

No Major Role of Common SV2A Variation for Predisposition or Levetiracetam Response in Epilepsy.

Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database

HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema

Genetic susceptibility to the cross-reactivity of aromatic antiepileptic drugs-induced cutaneous adverse reactions.

Levetiracetam Administration is Correlated with Lower Mortality in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes: a Retrospective Study